Methods and compositions for the assessment of drug response
OwnerPatrick A. Gladding, Marja-Liisa Dahl +1inventors
InventorsPatrick A. Gladding, Marja-Liisa Dahl, Mark W. Webster
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided
Claims13
A method comprising:
- a) analyzing a sample from a subject with a SNP detection assay to determine that said subject is homozygous for the −806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), thereby generating a homozygous CYP2C19*17 genetic analysis result;
- b) inputting said homozygous CYP2C19*17 genetic analysis result into a system, wherein said system comprises:
- i) a computer processor for receiving, processing, and communicating data,
- ii) a storage component for storing data which contains a reference genetic database of results of at least one genetic analysis of CYP2C19*17 homozygosity with respect to response to a thienopyridine anti-platelet agent, and
- iii) a computer program, embedded within said computer processor, which is configured to process said homozygous CYP2C19*17 genetic analysis result in the context of said reference database to determine, as an outcome, that said subject should receive decreased loading and/or maintenance dosages of said thienopyridine anti-platelet agent compared to CYP2C19 wild-type dosage levels;
- c) processing said homozygous CYP2C19*17 genetic analysis result with said computer program in the context of said reference database to generate said outcome;
- and
- d) communicating said outcome from said computer program, wherein said outcome indicates that said subject should receive decreased loading and/or maintenance dosages of said thienopyridine anti-platlet agent compared to CYP2C19 wild-type dosage levels.
A method comprising:
- a) analyzing a sample from a subject with a SNP detection assay to determine that said subject is homozygous for the −806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), thereby generating a homozygous CYP2C19*17 genetic analysis result;
- and
- b) processing said homozygous CYP2C19*17 genetic analysis result with a computer system to generate an outcome that indicates that said subject should receive decreased loading and/or maintenance dosages of thienopyridine anti-platelet agent compared to CYP2C19 wild-type dosage levels.
A method comprising:
- a) providing a subject that is homozygous for the −806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), and
- b) administering to said subject decreased loading and/or maintenance dosages of an thienopyridine anti-platelet agent compared to CYP2C19 wild-type dosage levels.
Dependencies are inferred from the claim text.